The studies examined SIMPONI’s ability to induce and maintain remission in patients with moderate to severe ulcerative colitis.
The study found that SIMPONI was able induce and maintain remission in a higher percentage of patients when compared to the placebo group. SIMPONI is designed as a treatment for patients who have failed to respond to conventional treatments.
More Articles on Gastroenterology:
Forecasting the Demand for Colonoscopy: 4 GI Physicians Weigh In
8 Statistics on Irritable Bowel Disease
2014 CPT Code Update: GI/Endoscopy
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
